Physician profile
Daniel Michael Moore
NPI 1669400990
$3,028.66
in general payments reported to CMS, 2019-2025
15 companies · $48.27 in 2025
The $48.27 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $642 · 2023: $1,034 · 2024: $924 · 2025: $48.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $595.66 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $539.10 | 2022-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Cvrx, INC. | $513.74 | 2022-2024 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $299.50 | 2023-2024 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $228.50 | 2024 | Optimizer |
| Abbott Laboratories | $146.16 | 2021-2025 | Aveir |
| Pfizer INC. | $144.79 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $142.91 | 2021-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.67 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $123.28 | 2023 | |
| Alnylam Pharmaceuticals INC. | $56.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $42.37 | 2023 | |
| Amgen INC. | $34.79 | 2023-2024 | Repatha |
| Medtronic, INC. | $24.23 | 2023 | Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.